Mutational patterns in therapy-related acute lymphoblastic leukemia subgroups: one step closer to unveiling the genetic odyssey

References

• Khoury JD, Solary E, Abla O, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–1719. doi:10.1038/s41375-022-01613-1
   PubMed Web of Science ®Google Scholar
• McNerney ME, Godley LA, Le Beau MM. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer. 2017;17(9):513–527. doi:10.1038/nrc.2017.60
   PubMed Web of Science ®Google Scholar
• Churpek JE, Larson RA. The evolving challenge of therapy-related myeloid neoplasms. Best Pract Res Clin Haematol. 2013;26(4):309–317. doi:10.1016/j.beha.2013.09.001
   PubMed Web of Science ®Google Scholar
• Ok CY, Patel KP, Garcia-Manero G, et al. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. J Hematol Oncol. 2015;8(1):45. doi:10.1186/s13045-015-0139-z
   PubMedGoogle Scholar
• Gibson CJ, Lindsley RC, Tchekmedyian V, et al. Clonal hematopoiesis associated With adverse outcomes After autologous stem-cell transplantation for lymphoma. J Clin Oncol. 2017;35(14):1598–1605. doi:10.1200/JCO.2016.71.6712
   PubMed Web of Science ®Google Scholar
• Kuzmanovic T, Patel BJ, Srinivasa R, et al. Genomics of therapy-related myeloid neoplasms. Haematologica. 2020;105(3):e98–e101. doi:10.3324/haematol.2019.219352
   PubMed Web of Science ®Google Scholar
• Saygin C, Kishtagari A, Cassaday RD, et al. Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood Adv. 2019;3(24):4228–4237. doi:10.1182/bloodadvances.2019000925
   PubMed Web of Science ®Google Scholar
• Barnea Slonim L, Gao J, Burkart M, et al. Therapy-related B-cell acute lymphoblastic leukemia in adults has unique genetic profile with frequent loss of TP53 and inferior outcome. Leukemia. 2021;35(7):2097–2101. doi:10.1038/s41375-020-01061-9
   PubMed Web of Science ®Google Scholar
• Kook HW, Kim JJ, Park MR, et al. Therapy-related acute lymphoblastic leukaemia has a unique genetic profile compared to de novo acute lymphoblastic leukaemia. J Cancer. 2022;13(12):3326–3332. doi:10.7150/jca.76719
   PubMed Web of Science ®Google Scholar
• Aldoss I, Stiller T, Tsai N-C, et al. Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients. Haematologica. 2018;103(10):1662–1668. doi:10.3324/haematol.2018.193599
   PubMed Web of Science ®Google Scholar
• Abdulwahab A, Sykes J, Kamel-Reid S, et al. Therapy-related acute lymphoblastic leukemia is more frequent than previously recognized and has a poor prognosis. Cancer. 2012;118(16):3962–3967. doi:10.1002/cncr.26735
   PubMed Web of Science ®Google Scholar
• Aldoss I, Stiller T, Song J, et al. Philadelphia chromosome as a recurrent event among therapy-related acute leukemia. American J Hematol. 2017;92(2):E18-E19. doi:10.1002/ajh.24604
   Web of Science ®Google Scholar
• Liehr T. International system for human cytogenetic or cytogenomic nomenclature (ISCN): some thoughts. Cytogenet Genome Res. 2021;161(5):223–224. doi:10.1159/000516654
   PubMed Web of Science ®Google Scholar
• Mayakonda A, Lin D-C, Assenov Y, et al. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747–1756. doi:10.1101/gr.239244.118
   PubMed Web of Science ®Google Scholar
• Ferraro F, Gao F, Stockerl-Goldstein K, et al. Secondary acute lymphoblastic leukemia, a retrospective analysis from Washington university and meta-analysis of published data. Leuk Res. 2018;72:86–91. doi:10.1016/j.leukres.2018.07.024
   PubMed Web of Science ®Google Scholar
• Pourhassan H, Yang D, Afkhami M, et al. High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia. American J Hematol. 2022;97(5):E171-E173. doi:10.1002/ajh.26490
   PubMed Web of Science ®Google Scholar
• Shivakumar R, Tan W, Wilding GE, et al. Biologic features and treatment outcome of secondary acute lymphoblastic leukemia—a review of 101 cases. Ann Oncol. 2008;19(9):1634–1638. doi:10.1093/annonc/mdn182
   PubMed Web of Science ®Google Scholar
• Vasudevan Nampoothiri R, Viswabandya A. Allogeneic hematopoietic stem cell transplantation in therapy related acute leukemia. Indian J Hematol Blood Transfus. 2021;37(4):521–527. doi:10.1007/s12288-020-01334-4
   PubMed Web of Science ®Google Scholar
• Ganzel C, Devlin S, Douer D, et al. Secondary acute lymphoblastic leukaemia is constitutional and probably not related to prior therapy. Br J Haematol. 2015;170(1):50–55. doi:10.1111/bjh.13386
   PubMed Web of Science ®Google Scholar
• Matnani R, Parekh V, Borate U, et al. Therapy-related B-lymphoblastic leukemia associated with philadelphia chromosome and MLL rearrangement: single institution experience and the review of the literature. Pathol Int. 2015;65(10):536–540. doi:10.1111/pin.12337
   PubMed Web of Science ®Google Scholar
• Lee S-G, Choi JR, Kim JS, et al. Therapy-related acute lymphoblastic leukemia with t(9;22)(q34;q11.2):a case study and review of the literature. Cancer Genet Cytogenet. 2009;191(1):51–54. doi:10.1016/j.cancergencyto.2009.02.002
   PubMedGoogle Scholar
• Riazat-Kesh YJRA, Mascarenhas J, Bar-Natan M. ‘Secondary’ acute lymphoblastic/lymphocytic leukemia - done playing second fiddle? Blood Rev. 2023;60:101070. doi:10.1016/j.blre.2023.101070
   PubMed Web of Science ®Google Scholar
• Tang G, Zuo Z, Thomas DA, et al. Precursor B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: is it therapy-related? Haematologica. 2012;97(6):919–925. doi:10.3324/haematol.2011.057752
   PubMed Web of Science ®Google Scholar
• Aldoss I, Douer D, Pullarkat V. Therapy-related acute lymphoblastic leukemia: where do we stand with regards to its definition and characterization? Blood Rev. 2019;37:100584. doi:10.1016/j.blre.2019.06.001
   PubMed Web of Science ®Google Scholar
• Bill M, Mrózek K, Kohlschmidt J, et al. Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A. Proc Natl Acad Sci USA. 2020;117(42):26340–26346. doi:10.1073/pnas.2014732117
   PubMed Web of Science ®Google Scholar